Phase I studies of hypericin, the active compound in St. John's wort, as an antiretroviral agent in HIV-infected adults: AIDS clinical trials group protocols 150 and 258

Annals of Internal Medicine

Volumn 130, Issue 6, 1999, Pages 510-514

  Gulick, Roy M ^a   McAuliffe, Vincent ^b   Holden Wiltse, Jeanne ^c   Crumpacker, Clyde ^d   Liebes, Leonard ^b   Stein, Daniel S ^e   Meehan, Patricia ^f   Hussey, Sheila ^d   Forcht, Janet ^b   Valentine, Fred T ^b  

^a Cornell University   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e GLAXOSMITHKLINE   (United States)

^f Biomedical Research Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EMODIN; HYPERICIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ERYTHEMA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERICUM PERFORATUM; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHOTOTOXICITY; PRIORITY JOURNAL; VIRUS TITRATION;

EID: 0033574149     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-130-6-199903160-00015     Document Type: Article

References (20)

1. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St. John's wort for depression - an overview and meta-analysis of randomised clinical trials. BMJ. 1996;313:253-8.
2. St. John's wort. Med Lett Drugs Ther. 1997;39:107-8.
3. Miller S. A natural mood booster Newsweek. 1997;5 May:74-5.
4. Kassler WJ, Blanc P, Greenblatt R. The use of medicinal herbs by human immunodeficiency virus-infected patients. Arch Intern Med. 1991;151: 2281-8.
5. Cooper WC, James J. An observational study of the safety and efficacy of hypericin in HIV+ subjects [Abstract]. Int Conf AIDS. 1990:6:369.
6. Furner V, Bek M, Gold J. A phase VII unblinded dose ranging study of hypericin in HIV-positive subjects [Abstract]. Int Conf AIDS. 1991;7:199.
7. Steinbeck-Klose A, Wernet P. Successful long term treatment over 40 months of HIV-patients with intravenous hypericin [Abstract]. Int Conf AIDS. 1993;9:470.
8. Tang J, Colacino JM, Larsen SH, Spitzer W. Virucidal activity of hypericin against enveloped and non-enveloped DNA and RNA viruses. Antiviral Res. 1990;13:313-25.
9. Lavie G, Valentine F, Levin B, Mazur Y, Gallo G, Lavie D, et al. Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin. Proc Natl Acad Sci U S A. 1989;86:5963-7.
10. Schinazi RF, Chu CK, Babu JR, Oswald BJ, Saalmann V, Eriksson BF, et al. Anthraquinones as a new class of antiviral agents against human immunodeficiency virus. Antiviral Res. 1990;13:265-72.
11. Hudson JB, Lopez-Bazzocchi I, Towers GHN. Antiviral activities of hypericin. Antiviral Res. 1991;15:101-12.
12. Degar S, Prince AM, Pascual D, Lavie G, Levin B, Mazur Y. et al. Inactivation of the human immunodeficiency virus by hypericin: evidence for photochemical alterations of p24 and a block in uncoating. AIDS Res Hum Retroviruses. 1992;8:1929-36.
13. Lenard J, Rabson A, Vanderoef R. Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: inhibition of fusion and syncytia formation. Proc Natl Acad Sci U S A. 1993;90:158-62.
14. Rodewald G, Arnold R, Griesler J, Steglich W. Synthesis of hypericin and related mesonapthodianthrones by alkaline dimerization of hydroxyanthraquinones. Angew Chem Int Ed Engl. 1977;16:46-7.
15. Evaluation of Certain Food Additives: Twenty-third Report of the Joint FAO/ WHO Expert Committee on Food Additives. Geneva: World Health Organization; 1980.
16. Woelk H, Burkard G, Grunwald J. Benefits and risks of the Hypericum extract LI 160: drug monitoring study with 3250 patients. J Geriatr Psychiatry Neural 1994;7 Suppl:S34-8.
17. Kerb R, Brockmoller J, Staffeldt B, Ploch M, Roots I. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother. 1996;40:2087-93.
18. Duran N, Song PS. Hypericin and its photodynamic action. Photochem Photobiol. 1986;43:677-80.
19. Giese AC. Hypericism. Photochemistry and Photobiology Review. 1980;5: 229-55.
20. Lavie G, Mazur Y, Lavie D, Prince AM, Pascual D, Liebes L, et al. Hypericin as an inactivator of infectious viruses in blood components. Transfusion. 1995;35:392-400.